Navigation Links
Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
Date:3/31/2008

Kingfisher's Revolutionary Device Designed to Improve Quality of Life for

Patients Suffering From Chronic Pain

ALBUQUERQUE, New Mexico, March 31 /PRNewswire/ -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market KFH Energy in the United States. The patented, high-tech medical device is intended to improve upon quality of life for sufferers of chronic pain associated with post-polio syndrome, fibromyalgia, multiple sclerosis, and chronic fatigue syndrome.

"We are thrilled to introduce KFH Energy to physicians, specialists, and patients throughout the United States," said Dr. Henk Snyman, CEO and co-founder of Kingfisher Healthcare, the parent company of Kingfisher Americas. "Our clinical research on post-polio patients yielded dramatic improvements, and we are eager to address the strong population of chronic pain patients in the U.S. With the proven success of KFH Energy, we anticipate that this technology will be the first in a suite of natural energy devices for a variety of treatments."

KFH Energy utilizes a unique form of micro current electrotherapy called Bio-Electric Stimulation Therapy (BEST), which is designed to enhance the body's physiological processes. Intended for home use, KFH Energy encapsulates this novel technology in a hand-held device. Its sleek and modern design elements, including the patented touch-screen panel, make the device both convenient and easy to use. KFH Energy received CE mark in Europe in September 2007.

"There is a growing demand among individuals with chronic pain for alternative treatments to improve their condition," said Herb Whitaker, CEO of Kingfisher Americas. "We are excited to have this device available in the States and are committed to improving the lives of those who have been sidelined as a result of symptoms." '/>"/>

SOURCE Kingfisher Americas
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
4. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
5. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
6. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
7. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
10. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
11. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart failure, ... is scheduled to present at the Bank of America Merrill ... on Thursday, May 14, 2015, at 10:00 a.m. ... the Company,s presentation at the conference will be available via ...
(Date:5/4/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) has ... (Bayer) to develop and commercialize ISIS-FXI Rx for ... agreement, Isis is eligible to receive up to $155 ... up-front payment and a $55 million payment upon advancement ... patients with compromised kidney function. Isis is also eligible ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... Inc. (NASDAQ: MSON ), a medical ... therapeutic ultrasonic products worldwide for wound debridement, cosmetic ... medical applications, today announced plans to release first ... Wednesday, November 9, 2011.  Michael A. McManus, President ...
...  Inova Labs, a privately held medical device company ... Pulmonary Disease (COPD) market, announced today that it has ... up to $17.5M from an investment syndicate led by ... company plans to use the capital to expand its ...
Cached Medicine Technology:Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern 2Inova Labs Closes on $17.5M Series B Financing 2
(Date:5/4/2015)... Fla. (PRWEB) May 04, 2015 ... Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke ... Target: Stroke Honor Roll. The award recognizes the ... patients receive the most appropriate treatment according to ... scientific evidence. , To receive the Gold Plus ...
(Date:5/4/2015)... NORTH HOLLYWOOD, Calif. (PRWEB) May 04, 2015 ... awards program recognizes IPC clinical leaders who have made ... to the patients they serve, both in acute and ... Hospitalist of the Year, Post-Acute Provider of the Year, ... the Year and Specialist Provider of the Year. Recipients ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 ... is now offering a more comfortable and attractive alternative ... restoration of choice for those who have lost teeth. ... can feel insecure or slip at the worst possible ... eats or talks. They can also painfully pinch or ...
(Date:5/4/2015)... May 04, 2015 CCL, a top-ranked, ... this unique program to other leadership development consultancies. “The ... between CCL and successful practitioners, expanding our capacity to ... globe,” said John R. Ryan, CCL President and CEO. ... CCL Partner Network , it will schedule a ...
(Date:5/4/2015)... 2015 Dr. Benjamin Stong of Kalos ... the latest non-surgical double-chin eliminator. Dr. Stong is ... in Atlanta to offer Kybella treatments . The ... specifically under the chin, promising to safely dissolve fat ... patients who sought immediate solutions for their double chin ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2
... Mom,s touch and diet Claire-Dominique Walker, PhD, ... The quality and quantity of maternal milk and maternal-infant ... according to recent research published in Developmental Psychobiology ... early in life can shape the physiology and behaviour ...
... N.C. A multidisciplinary team of University of North Carolina ... grant to develop computer models that will allow physicians to ... airway problems. The three co-principal investigators of the ... Stephanie Davis, MD, Chief of Pediatric Pulmonology in the School ...
... , THURSDAY, Feb. 3 (HealthDay News) -- ... and their doctors better understand the condition, a new ... a personal digital assistant (PDA) device. The patients used ... and other issues three times a day for 30 ...
... ANGELES (Feb. 2, 2011) A team of scientists from ... million grant from the California Institute for Regenerative Medicine ... discoveries for specific diseases. Additionally, another team ... million grant with a medical technology company aiming to develop ...
... HealthDay Reporter , WEDNESDAY, Feb. 2 (HealthDay News) -- ... increasingly common intestinal infection Clostridium difficile , which ... recurrence far better than currently used medications. Researchers ... drug often prescribed to C. difficile patients. ...
... By Maureen Salamon HealthDay Reporter , ... have devised a process to create ready-made, easily stored ... undergoing heart surgery or kidney dialysis. Using donor ... spent more than five years engineering the "off-the-shelf" blood ...
Cached Medicine News:Health News:Brains need love, too 2Health News:UNC researchers developing computer models for pediatric airway problems 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 2Health News:Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies 3Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 2Health News:New Antibiotic Helps Prevent Recurrence of Dangerous Gut Infection 3Health News:Researchers Craft Blood Vessels for Heart, Kidney Patients 2Health News:Researchers Craft Blood Vessels for Heart, Kidney Patients 3
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
... The IMMULITE chemiluminescent immunoassay system ... reliability, high-performance assays and fully integrated ... chosen for various types of immunoassay ... and breadth of menu., Assays for ...
AIA - Nex.IA immunoassay analyzer state of the art automation and flexibility for high throughput immunoassay testing...
... Immunoassay Analyzer that fits in any lab environment. ... 16 X 21 inches and weighs approximately 60 ... office laboratories, work stations for small hospitals, STAT ... a dedicated system for specialty testing. With a ...
Medicine Products: